CDRD & OICR Team Up to Advance Cutting-Edge New Cancer Treatments Two of Canada’s leading drug research and commercialization centers have announced a call for proposals to help bring new cancer treatments to patients through collaborative technology-development projects from academic investigators across Canada. [Center for Drug Research and Development (CDRD)] Press Release Sanofi and Regeneron Launch Major New Immuno-Oncology Collaboration Sanofi and Regeneron Pharmaceuticals, Inc. have entered into a new global collaboration to discover, develop and commercialize new antibody cancer treatments in the emerging field of immuno-oncology. [Sanofi] Press Release La Jolla Institute Announces Affiliation with UC San Diego Health The La Jolla Institute for Allergy and Immunology announced an official affiliation agreement with the University of California, San Diego Health System (UCSD). The multi-year agreement with UCSD will facilitate joint faculty appointments, enhance the range and depth of collaboration between the two organizations, and promote closer integration between basic immunology research and clinical medicine to speed the development of treatments for diseases of the immune system. [La Jolla Institute for Allergy and Immunology] Press Release Moffitt Cancer Center Teams Up with MD Anderson to Discover, Test Novel Agents to Prevent Cancer Moffitt Cancer Center has joined MD Anderson’s National Cancer Institute (NCI) Phase 0/I/II Cancer Prevention Clinical Chemoprevention Trials Consortia. Sponsored by the NCI’s Division of Cancer Prevention, the consortia conducts early clinical development of promising new preventive agents through its Phase 0/I/II Cancer Prevention Clinical Trials Program. [Moffitt Cancer Center] Press Release AstraZeneca and Heptares Therapeutics Enter Agreement to Develop Novel Immuno-Oncology Treatments AstraZeneca and Heptares Therapeutics announced that they have entered into a licensing agreement under which AstraZeneca will acquire exclusive global rights to develop, manufacture and commercialize the adenosine A2A receptor antagonist, HTL-1071, a small molecule immuno-oncology candidate, and potential additional A2A receptor-blocking compounds. [AstraZeneca] Press Release Sorrento In-Licenses Four Late-Stage Clinical Biobetter and Biosimilar Antibodies Sorrento Therapeutics, Inc. announced that it has entered into an exclusive licensing agreement to develop and commercialize multiple prespecified and undisclosed biosimilar or biobetter antibodies from Mabtech Limited, a holding company for premier antibody development and manufacturing companies in China. [Sorrento Therapeutics, Inc.] Press Release MabVax Therapeutics and The Rockefeller University Enter into a Collaborative Research Agreement MabVax Therapeutics Holdings, Inc. and The Rockefeller University’s Laboratory of Molecular Genetics and Immunology have entered into a research collaboration agreement to explore the mechanism of action of constant region variants of the HuMab 5B1 in the role of tumor clearance. [MabVax Therapeutics Holdings, Inc.] Press Release Bristol-Myers Squibb Establishes Collaborative Immuno-Oncology Rare Population Malignancy (I-O RPM) Program in the U.S. Bristol-Myers Squibb Company announced the establishment of the Immuno-Oncology Rare Population Malignancy (I-O RPM) program in the U.S. As part of the I-O RPM program, Bristol-Myers Squibb, the Robert H. Lurie Comprehensive Cancer Center of Northwestern University and the Northwestern Medicine Developmental Therapeutics Institute announced that they have entered into a collaboration agreement. [Bristol-Myers Squibb Company] Press Release University of Toronto to Transform Regenerative Medicine Thanks to Historic $114 Million Federal Grant The University of Toronto is set to cement its position as one of the world’s leading centers for the design and manufacture of cells, tissues and organs that can be used to treat degenerative disease, thanks to a $114-million grant from the federal government. [University of Toronto] Press Release Cell Therapy Catapult Awards Major Contract to Cellular Therapeutics Limited to Accelerate WT1 Clinical Program The Cell Therapy Catapult has awarded a manufacturing contract to Cellular Therapeutics Limited, to accelerate its clinical program to develop an engineered T cell treatment for blood cancers such as acute myeloid leukaemia and myelodysplastic syndrome. [Cellular Therapeutics Limited] Press Release Newcastle Gets £5 Million to Boost Drug Development Cancer Research UK’s Drug Discovery Committee has awarded Newcastle University’s Northern Institute of Cancer Research £5 million to bring more cancer drugs to clinical trials. [Cancer Research UK] Press Release Stem Cell Transplant Program Earns International Accreditation The Stem Cell Transplant Program at the University of Virginia Cancer Center has received international accreditation for its use of stem cells and bone marrow to treat patients with blood cancers. [University of Virginia Cancer Center] Press Release |